Intratumoral pan-ErbB targeted CAR-T for head and neck squamous cell carcinoma: interim analysis of the T4 immunotherapy study.

Autor: Papa S; School of Cancer & Pharmaceutical Sciences, King's College London, London, UK.; Department of Medical Oncology, Guy's and St Thomas' NHS Foundation Trust, London, UK., Adami A; School of Cancer & Pharmaceutical Sciences, King's College London, London, UK., Metoudi M; School of Cancer & Pharmaceutical Sciences, King's College London, London, UK., Beatson R; School of Cancer & Pharmaceutical Sciences, King's College London, London, UK., George MS; Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, UK., Achkova D; School of Cancer & Pharmaceutical Sciences, King's College London, London, UK., Williams E; Department of Immunobiology, School of Immunology & Microbial Sciences, King's College London, London, UK., Arif S; Department of Immunobiology, School of Immunology & Microbial Sciences, King's College London, London, UK., Reid F; School of Life Course & Population Sciences, King's College London, London, UK., Elstad M; School of Life Course & Population Sciences, King's College London, London, UK., Beckley-Hoelscher N; Department of Biostatistics and Health Informatics, Institute of Psychiatry Psychology & Neuroscience, King's College London, London, UK., Douri A; School of Life Course & Population Sciences, King's College London, London, UK., Delord M; School of Life Course & Population Sciences, King's College London, London, UK., Lyne M; Guy's and St Thomas' Biomedical Research Centre, Guy's and St Thomas' NHS Foundation Trust and King's College London, London, UK., Shivapatham D; Guy's and St Thomas' Biomedical Research Centre, Guy's and St Thomas' NHS Foundation Trust and King's College London, London, UK., Fisher C; Good Manufacturing Practice Unit, Guy's and St Thomas' Biomedical Research Centre, Guy's and St Thomas' NHS Foundation Trust, London, UK., Hope A; Good Manufacturing Practice Unit, Guy's and St Thomas' Biomedical Research Centre, Guy's and St Thomas' NHS Foundation Trust, London, UK., Gooljar S; Good Manufacturing Practice Unit, Guy's and St Thomas' Biomedical Research Centre, Guy's and St Thomas' NHS Foundation Trust, London, UK., Mitra A; Good Manufacturing Practice Unit, Guy's and St Thomas' Biomedical Research Centre, Guy's and St Thomas' NHS Foundation Trust, London, UK., Gomm L; Guy's and St Thomas' Biomedical Research Centre, Guy's and St Thomas' NHS Foundation Trust and King's College London, London, UK., Morton C; Department of Medical Oncology, Guy's and St Thomas' NHS Foundation Trust, London, UK.; Guy's and St Thomas' Biomedical Research Centre, Guy's and St Thomas' NHS Foundation Trust and King's College London, London, UK., Henley-Smith R; Head and Neck Pathology, Guy's and St Thomas' NHS Foundation Trust, London, UK., Thavaraj S; Head and Neck Pathology, Guy's and St Thomas' NHS Foundation Trust, London, UK.; Faculty of Dentistry, Oral and Craniofacial Sciences, Guy's Hospital, King's College London, London, UK., Santambrogio A; Faculty of Dentistry, Oral and Craniofacial Sciences, Guy's Hospital, King's College London, London, UK., Andoniadou C; Faculty of Dentistry, Oral and Craniofacial Sciences, Guy's Hospital, King's College London, London, UK., Allen S; Department of Nuclear Medicine, Guy's and St Thomas' NHS Foundation Trust, London, UK., Gibson V; Department of Nuclear Medicine, Guy's and St Thomas' NHS Foundation Trust, London, UK., Cook GJR; London School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK., Parente-Pereira AC; School of Cancer & Pharmaceutical Sciences, King's College London, London, UK., Davies DM; School of Cancer & Pharmaceutical Sciences, King's College London, London, UK., Farzaneh F; School of Cancer & Pharmaceutical Sciences, King's College London, London, UK., Schurich A; Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, UK., Guerrero-Urbano T; Department of Head and Neck Oncology, Guy's and St Thomas' NHS Foundation Trust, London, UK., Jeannon JP; Department of Head and Neck Oncology, Guy's and St Thomas' NHS Foundation Trust, London, UK., Spicer J; School of Cancer & Pharmaceutical Sciences, King's College London, London, UK.; Department of Medical Oncology, Guy's and St Thomas' NHS Foundation Trust, London, UK., Maher J; School of Cancer & Pharmaceutical Sciences, King's College London, London, UK john.maher@kcl.ac.uk.; Department of Immunology, Eastbourne Hospital, Eastbourne, UK.; Leucid Bio Ltd, London, London, UK.

Publikováno v: Journal for immunotherapy of cancer [J Immunother Cancer] 2023 Jun; Vol. 11 (6).

TGF-β1 potentiates Vγ9Vδ2 T cell adoptive immunotherapy of cancer.

Autor: Beatson RE; King's College London, School of Cancer and Pharmaceutical Sciences, Guy's Cancer Centre, Great Maze Pond, London SE1 9RT, UK., Parente-Pereira AC; King's College London, School of Cancer and Pharmaceutical Sciences, Guy's Cancer Centre, Great Maze Pond, London SE1 9RT, UK., Halim L; King's College London, School of Cancer and Pharmaceutical Sciences, Guy's Cancer Centre, Great Maze Pond, London SE1 9RT, UK., Cozzetto D; Translational Bioinformatics, NIHR Biomedical Research Centre, Guy's and St. Thomas's NHS Foundation Trust and King's College London, London SE1 9RT, UK., Hull C; King's College London, School of Cancer and Pharmaceutical Sciences, Guy's Cancer Centre, Great Maze Pond, London SE1 9RT, UK., Whilding LM; King's College London, School of Cancer and Pharmaceutical Sciences, Guy's Cancer Centre, Great Maze Pond, London SE1 9RT, UK., Martinez O; King's College London, School of Cancer and Pharmaceutical Sciences, Guy's Cancer Centre, Great Maze Pond, London SE1 9RT, UK., Taylor CA; King's College London, School of Cancer and Pharmaceutical Sciences, Guy's Cancer Centre, Great Maze Pond, London SE1 9RT, UK., Obajdin J; King's College London, School of Cancer and Pharmaceutical Sciences, Guy's Cancer Centre, Great Maze Pond, London SE1 9RT, UK., Luu Hoang KN; King's College London, School of Cancer and Pharmaceutical Sciences, Guy's Cancer Centre, Great Maze Pond, London SE1 9RT, UK., Draper B; King's College London, School of Cancer and Pharmaceutical Sciences, Guy's Cancer Centre, Great Maze Pond, London SE1 9RT, UK., Iqbal A; King's College London, School of Cancer and Pharmaceutical Sciences, Guy's Cancer Centre, Great Maze Pond, London SE1 9RT, UK.; Cancer Bioinformatics, King's College London, School of Cancer and Pharmaceutical Sciences, Guy's Cancer Centre, Great Maze Pond, London SE1 9RT, UK., Hardiman T; King's College London, School of Cancer and Pharmaceutical Sciences, Guy's Cancer Centre, Great Maze Pond, London SE1 9RT, UK.; Cancer Bioinformatics, King's College London, School of Cancer and Pharmaceutical Sciences, Guy's Cancer Centre, Great Maze Pond, London SE1 9RT, UK., Zabinski T; King's College London, School of Cancer and Pharmaceutical Sciences, Guy's Cancer Centre, Great Maze Pond, London SE1 9RT, UK., Man F; King's College London, School of Biomedical Engineering and Imaging Sciences, St. Thomas' Hospital, London SE1 7EH, UK., de Rosales RTM; King's College London, School of Biomedical Engineering and Imaging Sciences, St. Thomas' Hospital, London SE1 7EH, UK., Xie J; Bayer Healthcare Innovation Center, Mission Bay, 455 Mission Bay Boulevard South, San Francisco, CA 94158, USA., Aswad F; Bayer Healthcare Innovation Center, Mission Bay, 455 Mission Bay Boulevard South, San Francisco, CA 94158, USA., Achkova D; King's College London, School of Cancer and Pharmaceutical Sciences, Guy's Cancer Centre, Great Maze Pond, London SE1 9RT, UK., Joseph CR; King's College London, School of Cancer and Pharmaceutical Sciences, Guy's Cancer Centre, Great Maze Pond, London SE1 9RT, UK., Ciprut S; King's College London, School of Cancer and Pharmaceutical Sciences, Guy's Cancer Centre, Great Maze Pond, London SE1 9RT, UK., Adami A; King's College London, School of Cancer and Pharmaceutical Sciences, Guy's Cancer Centre, Great Maze Pond, London SE1 9RT, UK., Roider HG; Bayer AG, Müllerstrasse 178, 13342 Berlin, Germany., Hess-Stumpp H; Bayer AG, Müllerstrasse 178, 13342 Berlin, Germany., Győrffy B; Department of Bioinformatics, Semmelweis University, Budapest H1085, Hungary.; Cancer Biomarker Research Group, Research Center for Natural Science, Budapest H1117, Hungary., Quist J; King's College London, School of Cancer and Pharmaceutical Sciences, Guy's Cancer Centre, Great Maze Pond, London SE1 9RT, UK.; Cancer Bioinformatics, King's College London, School of Cancer and Pharmaceutical Sciences, Guy's Cancer Centre, Great Maze Pond, London SE1 9RT, UK., Grigoriadis A; King's College London, School of Cancer and Pharmaceutical Sciences, Guy's Cancer Centre, Great Maze Pond, London SE1 9RT, UK.; Cancer Bioinformatics, King's College London, School of Cancer and Pharmaceutical Sciences, Guy's Cancer Centre, Great Maze Pond, London SE1 9RT, UK., Sommer A; Bayer AG, Müllerstrasse 178, 13342 Berlin, Germany., Tutt ANJ; King's College London, Breast Cancer Now Unit, School of Cancer and Pharmaceutical Sciences, Guy's Cancer Centre, Great Maze Pond, London SE1 9RT, UK., Davies DM; King's College London, School of Cancer and Pharmaceutical Sciences, Guy's Cancer Centre, Great Maze Pond, London SE1 9RT, UK., Maher J; King's College London, School of Cancer and Pharmaceutical Sciences, Guy's Cancer Centre, Great Maze Pond, London SE1 9RT, UK.; Department of Immunology, Eastbourne Hospital, Kings Drive, Eastbourne, East Sussex BN21 2UD, UK.; Department of Clinical Immunology and Allergy, King's College Hospital NHS Foundation Trust, Denmark Hill, London SE5 9RS, UK.; Leucid Bio, Guy's Hospital, Great Maze Pond, London SE1 9RT, UK.

Publikováno v: Cell reports. Medicine [Cell Rep Med] 2021 Dec 21; Vol. 2 (12), pp. 100473. Date of Electronic Publication: 2021 Dec 21 (Print Publication: 2021).

CAR T-Cells Targeting the Integrin αvβ6 and Co-Expressing the Chemokine Receptor CXCR2 Demonstrate Enhanced Homing and Efficacy against Several Solid Malignancies.

Autor: Whilding LM; King's College London, School of Cancer and Pharmaceutical Studies, Guy's Hospital, Great Maze Pond, London SE1 9RT, UK. lynsey.whilding@kcl.ac.uk., Halim L; King's College London, School of Cancer and Pharmaceutical Studies, Guy's Hospital, Great Maze Pond, London SE1 9RT, UK. Leena.halim@kcl.ac.uk., Draper B; King's College London, School of Cancer and Pharmaceutical Studies, Guy's Hospital, Great Maze Pond, London SE1 9RT, UK. benjamin.draper@kcl.ac.uk., Parente-Pereira AC; King's College London, School of Cancer and Pharmaceutical Studies, Guy's Hospital, Great Maze Pond, London SE1 9RT, UK. anacatpp@gmail.com., Zabinski T; King's College London, School of Cancer and Pharmaceutical Studies, Guy's Hospital, Great Maze Pond, London SE1 9RT, UK. tomasz.zabinski@kcl.ac.uk., Davies DM; King's College London, School of Cancer and Pharmaceutical Studies, Guy's Hospital, Great Maze Pond, London SE1 9RT, UK. david.m.davies@kcl.ac.uk., Maher J; King's College London, School of Cancer and Pharmaceutical Studies, Guy's Hospital, Great Maze Pond, London SE1 9RT, UK. john.maher@kcl.ac.uk.; Department of Clinical Immunology and Allergy, King's College Hospital NHS Foundation Trust, London SE5 9RS, UK. john.maher@kcl.ac.uk.; Department of Immunology, Eastbourne Hospital, East Sussex BN21 2UD, UK. john.maher@kcl.ac.uk.

Publikováno v: Cancers [Cancers (Basel)] 2019 May 14; Vol. 11 (5). Date of Electronic Publication: 2019 May 14.

Chemotherapy-induced apoptosis, autophagy and cell cycle arrest are key drivers of synergy in chemo-immunotherapy of epithelial ovarian cancer.

Autor: Wahba J; Department of Surgery and Cancer, Institute of Reproductive and Developmental Biology, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London, W12 0NN, UK., Natoli M; Department of Surgery and Cancer, Institute of Reproductive and Developmental Biology, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London, W12 0NN, UK., Whilding LM; King's College London, Guy's Hospital Campus, London, UK., Parente-Pereira AC; King's College London, Guy's Hospital Campus, London, UK., Jung Y; Department of Surgery and Cancer, Institute of Reproductive and Developmental Biology, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London, W12 0NN, UK., Zona S; Department of Surgery and Cancer, Institute of Reproductive and Developmental Biology, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London, W12 0NN, UK., Lam EW; Department of Surgery and Cancer, Institute of Reproductive and Developmental Biology, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London, W12 0NN, UK., Smith JR; Department of Surgery and Cancer, Institute of Reproductive and Developmental Biology, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London, W12 0NN, UK., Maher J; King's College London, Guy's Hospital Campus, London, UK., Ghaem-Maghami S; Department of Surgery and Cancer, Institute of Reproductive and Developmental Biology, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London, W12 0NN, UK. s.ghaem-maghami@imperial.ac.uk.

Publikováno v: Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2018 Nov; Vol. 67 (11), pp. 1753-1765. Date of Electronic Publication: 2018 Aug 24.

CAR T-cell immunotherapy of MET-expressing malignant mesothelioma.

Autor: Thayaparan T; King's College London, Division of Cancer Studies, Guy's Hospital, Great Maze Pond, London SE1 9RT, UK., Petrovic RM; King's College London, Division of Cancer Studies, Guy's Hospital, Great Maze Pond, London SE1 9RT, UK., Achkova DY; King's College London, Division of Cancer Studies, Guy's Hospital, Great Maze Pond, London SE1 9RT, UK., Zabinski T; King's College London, Division of Cancer Studies, Guy's Hospital, Great Maze Pond, London SE1 9RT, UK., Davies DM; King's College London, Division of Cancer Studies, Guy's Hospital, Great Maze Pond, London SE1 9RT, UK., Klampatsa A; King's College London, Division of Cancer Studies, Guy's Hospital, Great Maze Pond, London SE1 9RT, UK.; Pulmonary, Allergy & Critical Care Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Parente-Pereira AC; King's College London, Division of Cancer Studies, Guy's Hospital, Great Maze Pond, London SE1 9RT, UK., Whilding LM; King's College London, Division of Cancer Studies, Guy's Hospital, Great Maze Pond, London SE1 9RT, UK., van der Stegen SJ; The Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Woodman N; King's College London, Division of Cancer Studies, Guy's Hospital, Great Maze Pond, London SE1 9RT, UK., Sheaff M; Department of Histopathology, Barts Health NHS Trust, The Royal London Hospital, London E1 2ES, UK., Cochran JR; Department of Bioengineering and Chemical Engineering, Stanford Cancer Institute, 443 Via Ortega, Room 356, Stanford, CA, USA., Spicer JF; King's College London, Division of Cancer Studies, Guy's Hospital, Great Maze Pond, London SE1 9RT, UK.; Department of Medical Oncology, Guy's and St Thomas' NHS Foundation Trust, London, UK., Maher J; King's College London, Division of Cancer Studies, Guy's Hospital, Great Maze Pond, London SE1 9RT, UK.; Department of Clinical Immunology and Allergy, King's College Hospital NHS Foundation Trust, Denmark Hill, London SE5 9RS, UK.; Department of Immunology, Eastbourne Hospital, Kings Drive, Eastbourne, East Sussex, BN21 2UD, UK.

Publikováno v: Oncoimmunology [Oncoimmunology] 2017 Aug 14; Vol. 6 (12), pp. e1363137. Date of Electronic Publication: 2017 Aug 14 (Print Publication: 2017).